Background. Among patients with fever and neutropenia during cancer chemotherapy who have a low risk of complications, oral administration of empirical broad-spectrum antibiotics may be an
Infection continues to be a major complication of neuorganism was fully susceptible, 3 and this led to the tropenia following cytotoxic chemotherapy and, despite requirement for synergistic combinations of antisignificant advances in the scope of antimicrobial drugs, microbial agents to give the bactericidal effect needed it is still responsible for considerable morbidity and a to treat infections in neutropenic individuals. The comsmall, but significant, mortality.
bination of a beta-lactam with an aminoglycoside apBoth the presentation and management of infection peared particularly suitable and, wherever possible, in the neutropenic patient differ from infection in other agents with activity against P aeruginosa were chosen. settings. A typical presentation is of fever with no other When extended spectrum penicillins such as piperacillin accompanying signs or symptoms, although about one and azlocillin became available, combinations of one of third of individuals may have some evidence of a source these with an aminoglycoside became widely used. 4 The of infection. Microbiological testing is also often dischanging pattern of infections, concerns about potential appointingly unhelpful, with a positive culture in less toxicity from the aminoglycosides, and the availability than 50% of patients. Once established, the course of of new broad spectrum, highly bactericidal antibiotics infection during neutropenia can be extremely rapid led to renewed interest in the possibility of monotherapy. and fulminating and it has become clear over the years Broad spectrum cephalosporins such as cefoperazone that it is essential to initiate antibiotic treatment as soon and ceftazidime were the first contenders to be studied, as a pyrexia is noted, and that it is dangerous to wait but a large trial carried out by the European Organisation to review the evolution of the process or to obtain for Research and Treatment of Cancer (EORTC) coma microbiological diagnosis. From these findings the paring ceftazidime with short or prolonged duration concept of empirical antibiotic treatment arose and the amikacin suggested that a full course of combination challenge has been to develop protocols for regimens therapy was more effective in individuals with Gram that are safe and effective that can respond to the negative bacteraemia. 5 This somewhat surprising result changing patterns of infection and the development of led to concerns about monotherapy which were not able antimicrobial resistance.
to be addressed until the availability of the carbapenem group of antimicrobial agents which have an extremely broad spectrum of activity and are highly bactericidal. Studies which looked initially at imipenem/cilastatin 6 7 Conventional management of febrile neutropenia and subsequently at meropenem 8 were able to confirm The rationale behind the very large numbers of pubthat these agents were as effective as combination relished clinical trials dealing with empirical treatment of gimens and had the potential for reduced toxicity. febrile neutropenia can be traced to the changing pattern With the increasing use of central venous catheters, of infection in neutropenic patients, the availability of the frequency of isolation of Gram positive bacteria, new antimicrobial agents and, more recently, attempts and the advent of widespread resistance to beta-lactam to improve safety and convenience of administration of antibiotics by coagulase negative staphylococci and, in these agents. some centres, Staphylococcus aureus, the question arose The changing pattern of infection in neutropenic as to whether a glycopeptide -either vancomycin or patients has been well documented. 1 2 During the 1970s teicoplanin -should become part of the initial empirical Gram negative bacilli were the predominant pathogens, regimen. This issue has been widely studied, including but this trend was reversed during the 1980s when a randomised trial coordinated by the EORTC, 9 and Gram positive bacteria began to account for some two the general conclusion has been that a glycopeptide thirds of documented infections and this pattern has should not be routinely added to the initial regimen, continued throughout the 1990s. The two major Gram although individual centres with particular problems positive bacteria accounting for this change have been with methicillin resistance might wish to consider adding the coagulase negative staphylococci, which are mainly one of these agents. related to the use of central venous catheters, and the New fluoroquinolones were another class of broad viridans streptococci which seem to be associated with spectrum antimicrobial agents with antipseudomonal intensive chemotherapeutic regimens, particularly those activity which came under consideration for use as which cause severe mucositis. Pseudomonas aeruginosa, empirical treatment for neutropenic fevers. Ciprowhich was previously an extremely important pathogen floxacin was the first of these agents to be developed in in this setting, is now isolated only infrequently. Relevant the mid 1980s and was obviously attractive for this advances in new antimicrobial agents have focused indication because of its spectrum, lack of resistance, particularly on the beta-lactam group, including the and the possibility of both intravenous and oral forcarbapenems, and the new fluoroquinolones.
mulations. The first studies of ciprofloxacin for the Early studies of treating febrile neutropenia showed poor results with aminoglycosides alone, even when the treatment of neutropenic fever were in the context group.bmj.com on May 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from of combinations of agents and used the intravenous uncontrolled malignancy; and group 4: outpatients with fever and neutropenia who did not have the additional formulation, although step down to the oral formulation was possible when patients had improved sufficiently. risk factors of groups 2 and 3. In two studies which attempted to validate whether the risk was different in The EORTC 10 undertook a prospective study comparing intravenous ciprofloxacin alone (200-300 mg these patient groups they were able to show a significantly higher risk of serious complications in groups every 12 hours) with piperacillin plus amikacin in patients with lymphoma and solid tumours, but this 1, 2, and 3 than in group 4. In addition, no deaths were noted in individuals identified as belonging to group 4, study was discontinued prematurely because patients treated with ciprofloxacin had a significantly lower overwhereas death rates in groups 1, 2, and 3 were between 9% and 23%. It is interesting that neither underlying all success rate than patients treated with piperacillin plus amikacin (65% versus 91%), as well as having a disease nor expected duration of neutropenia formed part of this risk assessment, and clinical characteristics poor outcome in those with Gram positive bacteraemia. By this time fluoroquinolones were being widely used which are often considered to be associated with additional risk -such as leukaemia (which may be related for prophylaxis of bacterial infections in neutropenic patients, and the authors concluded that empirical to expected prolonged duration of neutropenia), older age, bacteraemia, or hepatic dysfunction -were noted monotherapy with ciprofloxacin should not be recommended, even in patients with neutropenia of short in individuals in the low risk group 4. If this risk based approach was to be used to identify duration.
The Infectious Diseases Society of America 11 12 has a group of patients who were able to be managed as outpatients, other non-clinical risk factors such as attempted to produce comprehensive, evidence based guidelines for the use of antimicrobial agents in febrile availability of a capable carer, transport, and proximity to hospital would also need to be taken into account. neutropenia, and the most recently revised version of these continues to recommend that all febrile patients
To date, none of the studies attempting to validate a risk based strategy has assessed the potential numbers with neutrophil counts of <500/mm 3 and those with counts of 500-1000/mm 3 in whom a further decrease of patients with non-clinical risk factors that would make outpatient treatment dangerous or difficult. can be anticipated should be treated with broad spectrum bactericidal antibiotics by the intravenous route, although they acknowledge that a number of new issues need to be addressed including the identification of Options for management of low risk febrile neutropenia "lower risk" patients and the drive to reduce costs and enhance quality of life.
If a group of individuals at low risk of serious complications can be identified, then a number of options exist for lower intensity antimicrobial treatment. Clearly, to maximise benefits of cost saving and improved quality Rationale for a risk based approach Most of the large studies of various antibiotic regimens of life and to alleviate problems of access to healthcare facilities, particularly in developing countries, outpatient for febrile neutropenia have included patients with a wide variety of underlying diseases and expected durtreatment for all or part of the antimicrobial course is the ultimate goal. This could be achieved by sequential ation of neutropenia. In some cases patients perceived to have a different likely outcome, such as those with intravenous followed by oral antibiotics, outpatient intravenous treatment, or outpatient oral treatment. A solid tumours, were stratified into subgroups to ensure that they would be equally represented in the different number of studies of all these approaches have now been undertaken, but the major problem remains the trial arms but, in general, analyses have been of the full group of patients entered.
limited number of antimicrobial agents suitable for such use. However, it is well known that individuals with neutropenic fever are an extremely heterogeneous group and many factors are likely to influence the course of their infection and its outcome. In the mid 1960s Bodey    While it may be possible to train patients or their and colleagues 13 identified the association between depth of neutropenia and likelihood of infection and, carers to administer multiple daily doses of intravenous antibiotics, this is unlikely to find widespread acsince then, it has become clear that both degree and duration of neutropenia have a profound effect on risk ceptability, so the only realistic options for home intravenous treatment revolve around agents which can be of poor outcome from infection. Individuals with solid tumours are also considered to be at lower risk of serious administered once a day. Once daily aminoglycoside administration is well accepted and once daily amikacin complications, probably because chemotherapeutic regimens for these conditions usually result in shorter has been part of the regimen in a number of EORTC studies of febrile neutropenia. 8 18 However, regardless of periods of neutropenia. Episodes where a site of infection or causative organism cannot be identified (fevers of the dosing regimen, serum levels of aminoglycosides must be regularly monitored and this may prove to be unknown origin) tend to be associated with improved outcome, 14 but this cannot, of course, be identified until an added inconvenience in the outpatient setting. There are few options for beta-lactam agents which some time after presentation. Other factors which might play a role in determining risk of poor outcome had could be used either in combination with an aminoglycoside, another agent, or on their own. Ceftriaxone not, however, been carefully considered until the work of Talcott and colleagues. [15] [16] [17] In an attempt to identify has a long half life and its spectrum of activity includes many Gram positive cocci and Gram negative rods, but at presentation of fever a group of individuals at low risk of complications or death, they distinguished four not P aeruginosa. The efficacy and toxicity of single daily doses of ceftriaxone and amikacin were studied in a subgroups of patients -group 1: individuals who were already inpatients when fever developed; group 2: outlarge prospective randomised trial coordinated by the EORTC and compared with their "gold standard" repatients who had significant comorbidity other than the fever and neutropenia; group 3: outpatients who did gimen of multiple daily doses of ceftazidime and amikacin. 18 The single daily dosing regimen of ceftriaxone not have significant comorbidity but who did have group.bmj.com on May 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from and amikacin proved to be as effective and safe as the were given ofloxacin and instructed to self-administer it if fever developed. In this group 83% of the febrile standard treatment, and the authors noted that this could pave the way to a convenient intravenous treatepisodes responded to oral ofloxacin and did not require hospital admission, 15% failed and did need to be ment which could be used on an outpatient basis. Karthaus et al 19 studied 126 episodes of febrile neuadmitted to hospital, and in 2% the two patients did not respond and died before reaching hospital. Overall, tropenia in clinically stable outpatients which were treated with ceftriaxone alone in 100 episodes or in treatment was successful for 97% of all evaluable patients. In the second study 33 182 low risk febrile combination with other antibiotics in 26 episodes. The initial empirical regimen was successful in 78% of epineutropenic episodes were randomised to receive oral ofloxacin either at home or in hospital. Close monitoring sodes and 76% of the episodes were managed entirely in the outpatient setting. There were no infective deaths. and follow up was undertaken for all cases. Overall, 78% of inpatient and 77% of outpatient fevers resolved A number of other studies using ceftriaxone either alone or in combination with an aminoglycoside or a with no modification of initial treatment; 21% of patients originally assigned to outside management required adglycopeptide have also shown promising results. [20] [21] [22] mission to hospital. The mortality was 2% among inpatients and 4% among outpatients. One early death occurred in a non-hospitalised patient who developed    Where intravenous followed by oral or entirely oral vomiting and became unable to take oral medication but refused admission to hospital. Response rates were regimens are considered, the major class of antibiotics likely to be candidates are the fluoroquinolones. These significantly higher in cases of pyrexia of unknown origin than in proven infections and there were two cases of agents have a broad spectrum of activity, excellent oral bioavailability, and are well tolerated. However, breakthrough infections with P aeruginosa, calling into question whether ciprofloxacin would have been more the question of their safety in children remains controversial. 23 24 The first fluoroquinolone to be effective than ofloxacin.
In the United States, workers at the MD Anderson developed was ciprofloxacin, and ofloxacin and levofloxacin have since become widely available. A number Cancer Centre 34 studied a group of patients who did not require inpatient care for any other reason and of other newer agents are at various stages of development. In most of these newer agents the aim compared two outpatient regimens, one using intravenous clindamycin and aztreonam and the other oral has been to improve activity against Gram positive pathogens, in some cases at the expense of activity clindamycin together with oral ciprofloxacin 750 mg eight hourly. The patients studied included individuals against Gram negative organisms such as P aeruginosa. A major concern with the use of fluoroquinolones has with leukaemia and other haematological malignancies as well as those with solid tumours. Although the rebeen the development of resistance in Gram negative organisms, particularly E coli, in neutropenic cancer sponse rates were similar in both arms, the study was terminated early because of unacceptable toxicity in the patients, [25] [26] [27] and this is considered to be at least in part the result of the widespread practice of using these oral regimen. With this regimen there were four episodes of acute renal failure which was attributed to one or agents as prophylaxis against bacterial infections in these patient groups. A number of studies using ciprofloxacin more of several factors including the high dose of ciprofloxacin, a nephrotoxic interaction between clindamycin in combination with other intravenous agents have been reported, 28 29 and in a study comparing ciprofloxacin and ciprofloxacin, subclinical dehydration, or preexisting diminished renal function. plus netilmicin against piperacillin plus netilmicin, step down to oral ciprofloxacin therapy was possible in 64
A prospective randomised trial of outpatient treatment for low risk neutropenia was reported by Hidalgo of 115 (56%) episodes. 30 If an entirely orally based regimen is to be considered, et al. 35 Patients with solid tumours who presented with fever (>38°C) on two occasions four hours apart or the options are to use a fluoroquinolone on its own or to combine it with another agent. Malik and colleagues 38.5°C on one occasion and neutropenia of <500 cells/ l were randomised to receive hospital inpatient treatment have conducted a number of studies looking into the feasibility of using oral ofloxacin alone for neutropenic with intravenous ceftazidime and amikacin or outpatient oral ofloxacin. Exclusion criteria were ECOG percancer patients deemed to belong to low risk groups. These studies were carried out in Pakistan where the formance status 3-4, hypotension, oliguria, altered mental status, tachypnoea, respiratory failure, clotting availability of adequate medical services for the management of cancer is problematic and where many abnormality, acidosis, serious local infection, hypercalcaemia, and liver or renal failure. Patients were also individuals do not have adequate access to specialist facilities. In an initial small randomised study they noted excluded if they had received antibiotics in the last 96 hours. Ninety five of 100 randomised episodes were that oral ofloxacin at a dose of 400 mg twice daily was as effective as their current parenteral regimens using a evaluable; 89% of outpatients and 91% of inpatients recovered uneventfully. Eight patients (16%) in the beta-lactam together with amikacin. 31 However, patients with neutropenia of less than one week duration had outpatient group needed to be admitted to hospital because of treatment failure. No patients died during better responses to both treatment regimens than patients with longer lasting neutropenia. Mortality was the study. The authors concluded that oral ofloxacin was safe and similar in efficacy to broad spectrum 7% in the ofloxacin group and 10% in the parenteral therapy group. In two subsequent multicentre proparenteral antibiotics for low risk patients. spective trials the same group then addressed the issue of oral ofloxacin administered as an outpatient treatment. In the first study 32 a prerequisite of entry was inaccessibility to or non-affordability of conventional Myeloid growth factors in the treatment of neutropenia management. Neutropenic patients who were able to swallow, had no other comorbidities requiring admission Several guidelines have been published advising on how myelopoietic colony stimulating factors (CSFs) should to hospital, and in whom there was an expectation that neutropenia would not be prolonged beyond seven days, be used. 

Patients who had received autologous stem cell transplants were excluded from entering the study. Freifeld Secondary prophylaxis has been recommended for children receiving regimens which have previously caused et al allowed patients to be randomised for more than one episode, whereas Kern et al only enrolled patients prolonged neutropenia (>7 days) or severe neutropenia with associated proven bacterial or fungal infection once. The two groups had a different definition of neuwhich led to a modification of their chemotherapy regimen, or two previous episodes of prolonged and severe tropenia -<500/ml 3 in the study by Freifeld et al and <1000/ml 3 in the study by Kern et al. The latter group neutropenia with or without infection. G-CSF 5 g/kg/ day (Filgrastim) or 150 g/m 2 per day (Lenograstin) or stratified patients on entry to the study according to neutrophil count (<500 or ≥500). Fever was defined 5 g/kg/day (Molgramostim) should begin 1-5 days after chemotherapy, with a later start for regimens with a as ≥38°C on three oral measurements more than four hours apart during a 24 hour period or a single temlong half life, and should continue until the absolute neutrophil count exceeds 0.5×10 9 /l for two days. 36 perature of ≥38.5°C by Freifeld et al 40 or using the EORTC definition of ≥38.5°C on one occasion or Intervention therapy probably improves quality of life rather than survival as antibiotics are so effective. Two ≥38°C on two or more occasions within 12 hours by Kern et al. 41 placebo controlled trials in children have shown a statistically significant reduction of antibiotic days and durBoth groups used oral ciprofloxacin but the dose regimens were different -30 mg/kg/day in three divided ation of inpatient stay. Interventional use of CSFs is recommended for chemotherapy induced febrile neudoses (max 750 mg eight hourly) in the study by Freifeld et al or 15 mg/kg if weight <40 kg or 750 mg 12 hourly tropenia, together with antibiotics for children considered to be at high risk (proven pseudomonas or fungal in the study by Kern et al. Neither paper stipulated the timing of the first dose of oral treatment. Both groups infection, multi-organ dysfunction or pneumonia), and they are also recommended for prolonged neutropenia also used amoxycillin and clavulanate 40 mg/kg/day in three divided doses (maximum 500 mg eight hourly in of >28 days, with or without sepsis. Treatment is given until neutrophil counts are >0.5×10 9 /l for two conthe study by Friefeld et al) or 625 mg eight hourly or 15 mg/kg eight hourly if weight <40 kg in the study by secutive days and sepsis has resolved.
Kern et al. The standard intravenous antibiotic was different in the two trials; ceftazadime 90 mg/kg (max 2 g eight hourly) was used by Freifeld et al whereas  The American Society of Clinical Oncology (ASCO) 37 38 ceftriaxone 2 g was used in adults and amikacin 20 mg/ kg with dosage adjustment according to renal function and the EORTC 39 guidelines do not recommend use of CSFs in afebrile neutropenia, nor is routine use was used by Kern et al. The Freifeld study was double blind whereas the Kern study was of open label design. recommended in febrile neutropenic patients. Exceptions are patients at high risk of clinical deterioration A total of 211 patients were randomised in the Freifeld study with 284 episodes of fever of which 52 (18%) -for example, those with pneumonia, hypotension, multiorgan dysfunction or fungal infection -where the were not evaluable, leaving 232 evaluable episodes. Kern et al randomised 370 patients of whom 17 (5%) use of CSFs is thought to be reasonable although the benefits are not proven. The dose should be G-CSF were ineligible, giving 353 evaluable episodes. In both studies just over 70% of patients in each arm had solid 5 g/kg/day (Filgrastim) or 250 g/m 2 /day GM-CSF (Sargramostatin) intravenously or subcutaneously. The tumours. However, most of the patients in the Freifeld study had breast cancer and their mean age was 41-42 EORTC guidelines recommended CSFs for secondary prophylaxis after infections or neutropenia lasting more years, while in the study by Kern et al the median age was 52 years in each arm. than seven days following the first cycle of chemotherapy where treatment is given with curative intent and dose
In both groups central venous lines were present before the fever (170 (73%) episodes in the study by intensity should be maintained.
Freifeld et al and 143 (41%) episodes in the study by Kern et al). In addition, both groups had a high usage of myelopoietic growth factors. Freifeld et al used GMIntroductory articles Both of the introductory articles address the same issue CSF in 34 episodes (15%) and G-CSF in 163 episodes (70%) while Kern et al administered either G-CSF or -an evaluation of the efficacy of oral antibiotics in the management of fever associated with neutropenia after GM-CSF in 223 patients (63%). The reason for using CSF is not obvious but is assumed to be part of the cancer chemotherapy.
Patients were only included in the studies if they were chemotherapy protocol. The mean neutrophil count was 81/ml 3 for patients perceived to be at low risk -that is, had neutropenia that was expected to last no more than 10 days and receiving oral antibiotics and 84/ml 3 for patients randomised to receive intravenous therapy in the study by were haemodynamically stable. Freifeld et al 40 excluded patients with abdominal pain, nausea or vomiting, or
Freifeld et al whereas 78% of patients on oral antibiotics and 75% of those on intravenous antibiotics in the study diarrhoea more than six times daily whereas Kern et al 41 excluded patients who had signs or symptoms neby Kern et al had a neutrophil count of <100/ml 3 . The mean (Freifeld et al) or median (Kern et al) duration of cessitating intravenous supportive therapy. Both groups excluded patients with intravascular catheter infection, neutropenia was 3-4 days in both studies with no difference between the treatment groups. The cause catheter tunnel infection, neurological or mental status changes, or those who had received antibiotics within of approximately two thirds of febrile episodes was unexplained in both studies. the last 72 hours 40 or seven days. 41 Patients with new pulmonary infiltrates 40 or respiratory insufficiency 41 were The efficacy of antibiotic treatment was 71% for the oral route and 67% for the intravenous route in the also excluded from entry into the study. countries. The precise identification of the low risk subgroup is of patients receiving oral treatment and 32% receiving intravenous treatment had additional treatment which not yet clear. In some cases, as in the two publications reviewed, the decision making was based largely on resulted in one third of patients in each group needing treatment modifications. Fever of unknown origin was predicted duration of neutropenia, whereas in the model developed by Talcott and colleagues comorbidity and successfully treated by oral and intravenous antibiotics in approximately 85% of patients in each study, whereas the stage of malignancy were the major considerations. Further work on validating various rule based apmicrobiologically documented infection was successfully treated in only 41% of episodes treated with proaches would be helpful. In addition, if outpatient treatment is considered, non-clinical criteria for acoral antibiotics and 33% with intravenous antibiotics. 40 Kern et al 41 reported a success rate for bacteraemia ceptability of such an approach would need to be developed, such as the maximum distance from a and microbiologically documented infection without bacteraemia of 54% and 78%, respectively, for oral healthcare facility that the patient might be expected to travel, availability of carers, telephone and transport, antibiotics and 50% and 67%, respectively, for intravenous antibiotics.
and optimal timings for follow up to allow monitoring of other myelotoxicities such an anaemia and thromboFinberg and Talcott 42 wrote an accompanying editorial to these two articles which states that "the results cytopenia. It may be advisable to recommend supervision of the first dose of oral treatment to ensure that of these studies show that oral antibiotics may be safely substituted for intravenous antibiotics in low-risk it is taken promptly. A major problem with oral treatment of febrile neupatients with fever and neutropenia". However, in both of these studies patients were hospitalised and distropenia is that all regimens to date rely heavily on the use of a fluoroquinolone, either alone or in combination charged after resolution of fever and recovery of neutropenia to ≥500/ml 3 (Freifeld et al, not defined by with another agent. This is happening against a background of increasing availability of new quinolones, Kern et al). The frequency of blood pressure, temperature, pulse, and respiration rate is not documented many of which are being targeted for respiratory infections and are likely to be widely used both in hospitals for either study but patients were under close supervision with the ability to institute rapid changes in medication and the community. This will inevitably increase the potential for the development of resistance to this class should they deteriorate. One third of the patients in the study by Freifeld et al needed modifications to the of antimicrobial drug. Questions will arise as to whether it is safe to use repeated courses of the same agents in antibiotic regimen and both studies reported a lower efficacy for both oral and intravenous antibiotics in the a patient, or whether one could prescribe a fluoroquinolone for outpatient febrile neutropenia to an inpresence of microbiologically documented infection. There were no deaths in the study by Freifeld et al but dividual who has recently received one for another indication. Freifeld et al 40 and Kern et al 41 looked at Kern et al reported six deaths -two on oral antibiotics and four on intravenous antibiotics. The authors caution ciprofloxacin in combination with co-amoxiclav, whereas other workers have used a fluoroquinolone the extrapolation of these results to the use of oral antibiotics in outpatients.
alone with apparently equivalent results. If the treatment of febrile neutropenia with fluoroquinolones is to become widespread, their use in both prophylaxis and treatment of other conditions in cancer patients will have Conclusions There is now mounting evidence to suggest that it is to be carefully reviewed and surveillance of susceptibility patterns among clinical isolates from these patients will possible to identify a subset of neutropenic patients with cancer who have febrile episodes where the risk of be essential. Regardless of whether oral or even outpatient based complications or a poor outcome is low, and in whom LEARNING POINTS * Neutropenic sepsis is a medical emergency with a significant risk of mortality * A low risk group of patients may be identified, either on the basis of expected duration of neutropenia of <10 days, the absence of significant comorbidity, or both * Local policies should dictate the treatment approach based on patterns of infecting organisms and microbial susceptibility * Oral treatment for low risk patients appears to be as effective as intravenous treatment in randomised studies conducted in a hospital setting, although in some patients treatment will need to be modified because of intolerance or failure * There are few data on outpatient oral treatment in low risk patients, the feasibility of which must consider non-clinical variables such as suitable home circumstances group.bmj.com on May 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from
